← All trials
NCT06647732
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2024
- Primary completion
- Aug 31, 2028
- Completion date
- Sep 30, 2028
- First posted
- Oct 18, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Gansu Provincial HospitalCollaborator
- Guangzhou Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Capital Medical UniversityCollaborator
- Shenzhen UniversityCollaborator
- Sun Yat-Sen UniversitySponsor investigator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.